Withanolides and Withaferin A- What’s next in Ashwagandha Research

Authors: Krishnan P*

DOI: 10.23880/aabsc-16000232

Volume 7, Issue 2

Abstract

Ashwagandha (Withania somnifera), long valued in Ayurvedic medicine for its adaptogenic properties, has drawn significant interest due to the therapeutic potential of its key bioactives, withanolides. Among these, Withaferin A is the most studied, with promising applications beyond stress management, including cognitive health, inflammation, metabolic regulation, and cancer therapy. Preclinical studies suggest withanolides may promote neurogenesis, protect against neurodegenerative diseases like Alzheimer’s, and reduce oxidative stress and inflammation. Withaferin A’s immunomodulatory effects also show potential for managing autoimmune conditions like rheumatoid arthritis and multiple sclerosis. Additionally, the synergistic use of Withaferin A with other bioactives such as curcumin is being explored to enhance antioxidant and anti-inflammatory benefits. Withanolides have shown promise in improving metabolic health by regulating blood sugar and insulin sensitivity. Advances in delivery methods, such as liposomal and nanoemulsion formulations, are improving their bioavailability. Withaferin A’s anticancer properties, including its ability to induce apoptosis and inhibit tumor growth, highlight its potential in future cancer therapies. This review outlines current research and the expanding role of withanolides in preventive and therapeutic health.

Keywords: Withaferin; Ashwagandha; Health; Multiple Sclerosis (MS)

View PDF